Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 2050 of 3499 entries
View as:

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Phase: N/A Priority: Normal
NCT ID: NCT05715281 Org: User:
Start: 09/26/23 End: 10/15/26 Due: 10/15/27

Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00031928 Org: User:
Start: 01/31/02 End: - Due: -

Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

Phase: N/A Priority: Normal
NCT ID: NCT02001051 Org: User:
Start: 11/27/13 End: 02/26/18 Due: 02/26/19

Feasibility Study for Prospective Diet and Lifestyle Cohorts in Delhi, Kerala, and Kolkota, India

Phase: N/A Priority: Normal
NCT ID: NCT00341536 Org: User:
Start: 06/17/04 End: 11/20/13 Due: 11/20/14

Interleukin-12 in Treating Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00003330 Org: User:
Start: 07/31/98 End: - Due: -

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

Phase: N/A Priority: Normal
NCT ID: NCT06360588 Org: User:
Start: 10/08/18 End: 12/31/25 Due: 12/31/26

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06802523 Org: User:
Start: 07/25/25 End: 09/01/25 Due: 09/01/26

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00892736 Org: User:
Start: 04/20/09 End: 05/19/17 Due: 05/19/18

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00060372 Org: User:
Start: 04/30/03 End: - Due: -

Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00077155 Org: User:
Start: 12/31/03 End: - Due: -

Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00030485 Org: User:
Start: 01/31/02 End: 04/30/07 Due: 04/30/08

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01979523 Org: User:
Start: 10/23/13 End: 09/01/17 Due: 09/01/18

Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes

Phase: N/A Priority: Normal
NCT ID: NCT03830229 Org: User:
Start: 03/13/19 End: 07/05/27 Due: 07/05/28

Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00019461 Org: User:
Start: 04/30/98 End: 10/31/07 Due: 10/31/08

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00313586 Org: User:
Start: 08/31/06 End: 07/31/13 Due: 07/31/14

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01051934 Org: User:
Start: 12/29/09 End: 09/28/11 Due: 09/28/12

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Phase: N/A Priority: Normal
NCT ID: NCT02101905 Org: User:
Start: 11/07/16 End: 10/30/24 Due: 10/30/25

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00933985 Org: User:
Start: 06/30/09 End: 04/30/13 Due: 04/30/14

Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial

Phase: N/A Priority: Normal
NCT ID: NCT00941655 Org: User:
Start: 07/22/09 End: 06/18/12 Due: 06/18/13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04514497 Org: User:
Start: 10/20/21 End: 03/04/26 Due: 03/04/27

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00994500 Org: User:
Start: 08/31/09 End: - Due: -

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00986674 Org: User:
Start: 09/30/09 End: 12/31/13 Due: 12/31/14

Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

Phase: N/A Priority: Normal
NCT ID: NCT00064103 Org: User:
Start: 06/30/03 End: - Due: -

Gastric Cancer Precursor Lesions (GCPL) Study

Phase: N/A Priority: Normal
NCT ID: NCT03188406 Org: User:
Start: 05/02/17 End: 04/28/20 Due: 04/28/21

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04941287 Org: User:
Start: 12/15/21 End: 04/29/26 Due: 04/29/27